Moderna, Inc. - Common Stock (MRNA)

BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) is advancing its Sapu003 program and Deciparticle(TM) platform as key components of a wider industry shift toward scalable nanotechnology-driven drug delivery and AI-enhanced biomedical infrastructure. The company’s approach centers on leveraging platform technologies that may serve multiple therapeutic applications across oncology and rare disease markets rather than depending on a solitary drug candidate. Oncotelic is among several companies, including CytoDyn Inc. (OTCQB: CYDY), Revolution Medicines Inc. (NASDAQ: RVMD), Moderna Inc. (NASDAQ: MRNA) and Sarepta Therapeutics Inc. (NASDAQ: SRPT), that are developing scalable biotechnology platforms designed to support multiple therapeutic programs across diverse disease areas, distinguishing…

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial exploring how biotechnology companies are increasingly leveraging advanced drug-delivery technologies, nanotechnology platforms and artificial intelligence to enhance existing therapies and expand treatment opportunities. The article highlights Oncotelic’s Sapu003 program, Deciparticle(TM) platform and PDAOAI initiative as part of a broader industry trend toward scalable, multi-application biotechnology platforms capable of supporting oncology and rare disease programs.

CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) is advancing its Sapu003 program and Deciparticle(TM) platform as key components of a wider industry shift toward scalable nanotechnology-driven drug delivery and AI-enhanced biomedical infrastructure. The company's approach centers on leveraging platform technologies that may serve multiple therapeutic applications across oncology and rare disease markets rather than depending on a solitary drug candidate. Oncotelic is among several companies, including CytoDyn Inc. (OTCQB: CYDY), Revolution Medicines Inc. (NASDAQ: RVMD), Moderna Inc. (NASDAQ: MRNA) and Sarepta Therapeutics Inc. (NASDAQ: SRPT), that are developing scalable biotechnology platforms designed to support multiple therapeutic programs across diverse disease areas, distinguishing them from traditional single-asset biotechnology companies.

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA alone

Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies. The recognition highlights the Company's work as a pioneer of mRNA technology and its focus on delivering meaningful benefits for patients and society.

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and…

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself within a growing push to overcome one of modern medicine’s most persistent challenges: delivering therapeutics effectively across the blood-brain barrier. Through its proprietary intranasal nose-to-brain delivery platform, the company is pursuing targeted central nervous system applications spanning Alzheimer’s disease and biodefense, reflecting broader industry recognition that delivery technology may be as critical as drug discovery itself. Oncotelic is part of an innovative therapeutic landscape that includes Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (N2B) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product

CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS>1%)

CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report its first quarter 2026 financial results, and provide a corporate update.

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026.

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive CHMP opinion

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board.

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:

Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review

mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe